Trial Profile
Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 19 Sep 2019 Status changed from not yet recruiting to discontinued.
- 05 Sep 2014 New trial record